Amgen and GSK are the latest major pharmaceutical companies to join TrumpRx.gov, a government website offering prescription drug discounts under most-favored-nation pricing, according to FOX Business. This expansion brings the total to 54 prescription medications from six pharmaceutical companies participating in the program, which has been driven by President Donald Trump and the threat of tariffs [1]. Amgen will offer Amjevita at an 80% discount, reducing the price from $1,484 to $299. Additionally, Amgen plans to list Aimovig and Repatha at discounts of 62% [1]. GSK will discount Incruse, a COPD treatment, by 55%, listing it at $159, and will also offer Arnuity, Relenza, and Anoro at discounts ranging from 10% to 51% [1].
Market reaction to the news was modest, with Amgen's stock (AMGN) closing at $366.21, down 0.43%, and GSK's stock (GSK) at $53.39, down 1.64% [1]. White House spokesman Kush Desai described the move as a milestone for President Trump’s affordability push, stating that TrumpRx.gov is just the beginning and that Americans are expected to receive even greater drug pricing discounts, lower insurance premiums, and more transparency when Congress passes President Trump’s Great Healthcare Plan [1].
However, the Pharmaceutical Research and Manufacturers of America, represented by CEO Stephen Ubl, criticized the most-favored-nation policies, arguing that they would undermine U.S. competitiveness, siphon billions from American R&D, slow the pace of cures, and increase reliance on China for future innovation [1].
Prescription drug costs have shown different trends under recent administrations. Bureau of Labor Statistics data indicates that under the Biden administration, prescription drug costs increased 10.4% from January 2021 to January 2025, while under the Trump administration, prices increased only 0.2% from January 2025 through February 2026 [1].
CONCLUSION
The addition of Amgen and GSK to TrumpRx.gov marks a significant step in President Trump’s push for drug affordability, offering substantial discounts on key medications. While the market response was muted, the initiative is expected to provide greater savings and transparency for consumers. Industry criticism highlights concerns about long-term innovation and competitiveness, but the White House remains committed to expanding the program.